May 20, 2024

Prurigo Nodularis Treatment Market Size, Share, Report by 2033

The global prurigo nodularis treatment market size was estimated at USD 2.13 billion in 2023 and is projected to reach around USD 3.17 billion by 2033, growing at a CAGR of 4.03% from 2024 to 2033.

Key Points

  • The North America prurigo nodularis treatment market size accounted for USD 870 million in 2023 and is expected to attain around USD 1,300 million by 2033.
  • North America dominated the market with the major market share of 41% in 2023.
  • Asia Pacific is estimated to be the fastest growing during the forecast period of 2024-2033.
  • By product type, the corticosteroids segment has held the biggest market share of 37% in 2023.
  • By product type, the antihistamines segment is estimated to be the fastest growing during the forecast period.
  • By distribution channel type, the retail pharmacies segment has contributed more than 42% of market share in 2023.
  • By distribution channel type, the online pharmacies segment is expected to be the fastest growing during the forecast period.

Prurigo Nodularis Treatment Market Size 2024 to 2033

Prurigo nodularis is a chronic skin condition characterized by intensely itchy nodules or papules on the skin. The prurigo nodularis treatment market encompasses various therapies aimed at managing this condition. These treatments focus on reducing itchiness, inflammation, and the appearance of nodules to improve patients’ quality of life.

Get a Sample:

Growth Factors

The growth of the prurigo nodularis treatment market is driven by several factors. First, an increasing prevalence of prurigo nodularis worldwide has led to a greater demand for effective treatments. Additionally, advancements in medical research and technology have facilitated the development of novel therapies with improved efficacy and safety profiles. Moreover, rising awareness among healthcare professionals and patients about the impact of prurigo nodularis on overall well-being is driving the market forward.

Region Insights

The market for prurigo nodularis treatment exhibits regional variations in terms of treatment availability, healthcare infrastructure, and patient demographics. Developed regions such as North America and Europe typically have better access to advanced treatment options and higher healthcare expenditure, contributing significantly to market growth. Emerging economies in Asia-Pacific and Latin America are also witnessing increased attention towards prurigo nodularis treatment, driven by improving healthcare facilities and rising disease awareness.

Prurigo Nodularis Treatment Market Scope

Report Coverage Details
Prurigo Nodularis Treatment Market Size in 2023 USD 2.13 Billion
Prurigo Nodularis Treatment Market Size in 2024 USD 2.22 Billion
Prurigo Nodularis Treatment Market Size by 2033 USD 3.17 Billion
Growth Rate from 2024 to 2033 CAGR of 4.03%
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product Type and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Prurigo Nodularis Treatment Market Dynamics


Key drivers of the prurigo nodularis treatment market include the development of targeted therapies specifically designed to address the underlying mechanisms of the condition. Additionally, supportive regulatory environments that expedite the approval process for novel treatments encourage pharmaceutical companies to invest in research and development for prurigo nodularis. Moreover, collaborations between academia, industry, and advocacy groups foster innovation and accelerate the introduction of new therapeutic options.


Opportunities in the prurigo nodularis treatment market lie in the exploration of alternative treatment modalities such as biologics, topical agents, and neuromodulators. Furthermore, expanding market penetration into underserved regions and patient populations presents a promising avenue for growth. Personalized medicine approaches that tailor treatments based on individual patient characteristics and disease profiles also represent a significant opportunity for market expansion.


Despite the progress in prurigo nodularis treatment, several challenges persist. Limited understanding of the disease pathophysiology complicates the development of targeted therapies. Additionally, high treatment costs and reimbursement issues may restrict patient access to effective treatments. Furthermore, the chronic nature of prurigo nodularis necessitates long-term management strategies, posing challenges in terms of treatment adherence and patient compliance.

Read Also: Medical Gas Market Size to Reach USD 32.47 Billion by 2033

Prurigo Nodularis Treatment Market Recent Developments

  • In February 2023, Pfizer’s supplemental new drug applications (NDA) for abrocitinib (CIBINQO) was announced by the United States (U.S.) Food and Drug Application (FDA) for the treatment of serious atopic dermatitis, refractory, skin clearance, itching, severity, and disease extent for the 12 to less than 18 years of age group.
  • In October 2023, new positive pruritus data for VTAMA Cream from their essential phase 3 trials was announced by a clinical-stage biopharmaceutical company, Dermavant Sciences (tapinarof). This is for children as young as two years old, and 1% of adults suffer from atopic dermatitis. It is also important to reduce itching, burning, redness, and itching.
  • In February 2024, the Food and Drug Administration (FDA) accepted Galderma’s BLA (biological license application) for Nemolizumab to treat atopic dermatitis and prurigo nodularis.

Prurigo Nodularis Treatment Market Companies

  • Bayer AG
  • Celgene Corporation
  • Glaxo Smith Kline plc
  • Galderma Takeda Pharmaceuticals (Nestle Skin Health Company)
  • Johnson & Johnson Services Inc.
  • Merk & Co. Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Inc
  • VYNE Therapeutics Inc.

Segments Covered in the Report

By Product Type

  • Antihistamines
  • Capsaicin Cream
  • Corticosteroids
  • Emollients
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333






Leave a Reply

Your email address will not be published. Required fields are marked *